Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | PDE2A | O00408 | 3/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.42 |
| ▸ | PPARG | P37231 | 2/20 | 0.42 |
| ▸ | PPARA | Q07869 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.40 |
| ▸ | PPARD | Q03181 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5916381 | 0.79 | LMNA (0.44) | ALDH1A1POLB | |
| SCHEMBL7260554 | 0.78 | CYP2C9 (0.39) | ALDH1A1POLB | |
| SCHEMBL27887474 | 0.77 | AKR1C3 (0.54) | HRH3ALDH1A1PDE2AEPHX2PPARG | |
| SCHEMBL16738660 | 0.76 | ALDH1A1 (0.48) | ALDH1A1PPARGPPARA | |
| SCHEMBL9052921 | 0.73 | CYP2C9 (0.55) | PPARGPPARA | |
| SCHEMBL26239331 | 0.73 | ALDH1A1 (0.43) | HRH3ALDH1A1PDE2AEPHX2PPARG | |
| SCHEMBL4542016 | 0.73 | PDE2A (0.54) | HRH3ALDH1A1PDE2APOLB | |
| SCHEMBL27665402 | 0.72 | HRH3 (0.40) | HRH3ALDH1A1PDE2AEPHX2PPARG | |
| SCHEMBL7215573 | 0.72 | ITGA4 (0.43) | ALDH1A1MRGPRX4 | |
| SCHEMBL20032388 | 0.72 | PDE2A (0.53) | HRH3ALDH1A1PDE2AEPHX2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9469637-B2 | Nitrogenated heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-10-18 | — | — | US | disclosed |
| US-20150105373-A1 | NITROGENATED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105373-A1 | NITROGENATED HETEROCYCLIC COMPOUND | PDE2A, PDE5A, PDE3A | HRH3 3112/4885ALDH1A1 492/4885PDE2A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.